Amgen Inc. (AMGN:NASDAQ)
Snapshot of Amgen Inc. (AMGN)
|
OPEN
$55.79
|
PREVIOUS CLOSE
$56.06
|
|
|
DAY HIGH
$55.79
|
DAY LOW
$55.12
|
|
|
52 WEEK HIGH
08/13/09 - $64.76
|
52 WEEK LOW
04/22/09 - $44.96
|
|
|
MARKET CAP
56.1B
|
AVERAGE VOLUME 3 mo
6.0M
|
|
|
DILUTED EPS TTM
$4.49
|
SHARES OUTSTANDING
1.0B
|
|
|
AMGN Does Not Pay Dividends
|
P/E TTM
12.3x
|
|
| K = Thousands M = Millions B = Billions | ||
related business week news
Wall Street analysts give their buy, sell, or hold views on 10 stocks in the news this week
Wall Street analysts give their buy, sell, or hold views on 10 stocks in the news this week
Plus Wall Street analyst opinions on F5 Networks and TriQuint Semiconductor
Why the U.S. faces a jobless recovery and what can be done to change that
related news
AMGN Details
Amgen Inc., a biotechnology company, engages in the discovery, development, manufacture, and marketing of human therapeutics based on advances in cellular and molecular biology. The company markets human therapeutic products primarily in the areas of supportive cancer care, nephrology, and inflammation. Its principal products include Aranesp and EPOGEN that stimulate the production of red blood cells to treat anemia; Neulasta and NEUPOGEN, which selectively stimulate the production of neutrophils, a type of white blood cell that helps the body fight infections; and ENBREL that blocks the biologic activity of tumor necrosis factor by inhibiting TNF, a substance induced in response to inflammatory and immunological responses, such as rheumatoid arthritis and psoriasis. The company has a joint venture with Kirin Holdings Company, Limited to manufacture and market darbepoetin alfa; a co-promotion agreement with Wyeth for marketing and selling of ENBREL; and Johnson & Johnson to commercialize recombinant human erythropoietin as a human therapeutic. It markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies primarily in the United States, Europe, and Canada. The company was founded in 1980 and is based in Thousand Oaks, California.
AMGN Top Compensated Officers
Key developments for Amgen Inc. (AMGN)
Amgen Inc. - Conference Presentation Calls
Amgen Inc. - Conference Presentation Calls
Amgen Inc. announced that the Phase 3 PRIME '203' trial evaluating Vectibix® (panitumumab) administered in combination with FOLFOX (an oxaliplatin-based chemotherapy) as a first-line treatment of metastatic colorectal cancer (mCRC) failed to meet a secondary endpoint of overall survival. The prospective analysis of the 203 study showed that Vectibix, when added to a FOLFOX chemotherapy regimen in patients with KRAS wild-type mCRC, resulted in a median overall survival of 23.9 months compared to 19.7 months for patients treated with FOLFOX alone. The median overall survival difference of 4.2 months in the Vectibix arm did not reach statistical significance (HR=0.83, p=0.072). Further, the addition of Vectibix to chemotherapy also improved response rate in the KRAS wild-type patient population as measured by blinded central review (55% versus 48% in the FOLFOX only arm). The data for the 203 study has been submitted for consideration of presentation at the American Society of Clinical Oncology-The Gastrointestinal Cancers Symposium Meeting for 2010.
BusinessWeek Rankings
Stock Quotes
| Recently Viewed | |||
| AMGN | $55.38 USD | -0.68 |  |
|---|---|---|---|
| MRK | $36.46 USD | +1.13 |  |
| KPN (NL) | €11.60 EUR | -0.285 |  |
| GCI | $10.38 USD | -0.51 |  |
| SBUX | $21.41 USD | -0.12 |  |
Market data is delayed at least 20 minutes.
AMGN Competitors
| Company | Last | Change |
| Astellas Pharma Inc | ¥3,200 JPY | -80.00 |
| Baxter International Inc | $54.33 USD | -0.62 |
| Fresenius Medical Care | €35.77 EUR | +0.06 |
| Merck KGAA | €64.23 EUR | +0.19 |
| Takeda Pharmaceutical Co Ltd | ¥3,540 JPY | -10.00 |
| View Industry Companies | ||
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | AMGN | Industry Range |
| Price/Earnings | 12.1x |
|
| Price/Sales | 3.9x |
|
| Price/Book | 2.5x |
|
| Price/Cash Flow | 11.1x |
|
| TEV/Sales | 2.1x |
|
|
AMGN |
||
AMGN transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
Companies Toolbox
Update/report
Submit private company
Upload your company video
Newsletter
Blogs
RSS feeds
Podcasts
VideosSEARCH FOR JOBS
Post a Job- Thousand Oaks, CA-Amgen
- Thousand Oaks, CA-Amgen
- Thousand Oaks, CA-Amgen
- Thousand Oaks, CA-Amgen
Jobs by SimplyHired
Recommend A Data Enhancement Or Correction
For Amgen Inc. (AMGN) Snapshot
Submitting this data update / error report instantly puts the correct information in the hands of our researcher, who will investigate your report and, if necessary, make the changes to the company profile. Be sure to fill out the form completely.
Please indicate in which section the error appears. Section headers are in light gray type at the top of each CIC page module.
Please indicate which data is in error.
Please provide your name and email address in case our researchers need to get in touch with you as they investigate the error.
Describe why you feel the data point is incorrect and indicate sources our researchers should check when they investigate the error.
